Results 201 to 210 of about 146,360 (265)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

The Association Between Active Aging and Health-Related Quality of Life. [PDF]

Geriatrics (Basel)
Woo K, Lee J, Choy Y.
europepmc   +1 more source

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

Arthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken, Jeremy M Weber, Megan L Neely, Aparna C Swaminathan, Scott M Palmer, Erin M Wilfong, Ann D Chauffe, Elizabeth R Volkmann   +7 more
wiley   +1 more source

Patterns of CDSS adoption in primary care: a cluster analysis and predictive modelling study from a stepped wedge trial. [PDF]

Implement Sci
Basten J, Köberlein-Neu J, Ihle P, Meyer I, Timmesfeld N, eHealth COMPATH Study Group.   +5 more
europepmc   +1 more source

Policy lessons regarding medical security for rare diseases inChina: Insights from Zhejiang Province through the multiplestreams framework. [PDF]

Intractable Rare Dis Res
Wang M, Rong C, Wang P.
europepmc   +1 more source

Access to care during COVID-19: A qualitative study of healthcare system resilience in San Antonio, Texas. [PDF]

J Public Health Res
Ovuegbe S, Collier A, Forrest D, McKieran L, Tsai J.   +4 more
europepmc   +1 more source

Recruitment and Participation of Black Home Health Care Patients in Speech-Based Cognitive Research: Mixed Methods Feasibility Study. [PDF]

JMIR Form Res
Spens I, Zhang Z, Azadmaleki H, Vergez S, Flaherty G, Onorato N, Noble JM, McDonald M, Zolnoori M.   +8 more
europepmc   +1 more source

Modeling Financial Insolvency and Income Loss Insurance in Head and Neck Cancer. [PDF]

J Health Econ Outcomes Res
Araujo AV, Bartho MJ, Low GMI, Li RJ.
europepmc   +1 more source